Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Gross Margin: 2017-2021

Historic Gross Margin for Neurocrine Biosciences (NBIX) over the last 5 years, with Sep 2021 value amounting to 98.58%.

  • Neurocrine Biosciences' Gross Margin fell 37.00% to 98.58% in Q3 2021 from the same period last year, while for Sep 2021 it was 99.78%, marking a year-over-year increase of 72.00%. This contributed to the annual value of 99.06% for FY2019, which is 14.00% up from last year.
  • Per Neurocrine Biosciences' latest filing, its Gross Margin stood at 98.58% for Q3 2021, which was down 0.35% from 98.93% recorded in Q2 2021.
  • Neurocrine Biosciences' 5-year Gross Margin high stood at 99.29% for Q3 2017, and its period low was 98.58% during Q3 2021.
  • Its 3-year average for Gross Margin is 98.99%, with a median of 98.99% in 2019.
  • In the last 5 years, Neurocrine Biosciences' Gross Margin skyrocketed by 54bps in 2019 and then plummeted by 37bps in 2021.
  • Over the past 5 years, Neurocrine Biosciences' Gross Margin (Quarterly) stood at 99.20% in 2017, then tumbled by 36bps to 98.83% in 2018, then grew by 13bps to 98.96% in 2019, then fell by 5bps to 98.96% in 2020, then crashed by 37bps to 98.58% in 2021.
  • Its last three reported values are 98.58% in Q3 2021, 98.93% for Q2 2021, and 98.77% during Q1 2021.